a
a
Weather:
No weather information available
HomeHealthZynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

PENNINGTON, N.J., March 12, 2025 /PRNewswire/ — Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral…

No comments

Sorry, the comment form is closed at this time.

Translate »